DONATE

Nuria Montserrat will coordinate from IBEC the new national platform for biobanks and biomodels

The newly created Platform will manage biological samples of disease through the coordination of supply services including, also, conventional samples through virtual biobanks. In turn, the Platform will work on the development of services in the field of organoids, animal models and 3D tissue printing.

Redirect the platforms of the Carlos III Health Institute (ISCIII) to face three major challenges. To this end, the Council of Ministers approved in 2020, at the request of the Ministry of Science and Innovation, to authorize the ISCIII to call for grants for the ISCIII Platforms to support R&D&I in Biomedicine and Health Sciences, as part of the development of the Strategic Action in Health 2017-2020. 

Among these, the newly created Biobanks and Biomodels Platform will manage, with the coordination of the ICREA Research Professor at IBEC, Nuria Montserrat, biological samples of disease by coordinating the supply and generation of organoids and/or animal models, 3D printing of organs and tissues. The platform will also manage conventional samples thanks to virtual biobanks. As one of the members of the State Research and Innovation Platform, Nuria Montserrat at IBEC has obtained funding of 354.442 euros and, on the other hand, has a budget of 406.500 euros to carry out the coordination of the Platform for Biobanks and Biomodels. 

 

ISCIII Platforms, at the service of health. 

The ISCIII Platforms are a set of research centers and groups that share their high-level scientific-technical capacities with research groups of the National Health System (SNS), and with a clear orientation to health sciences, to patients and their families. These Platforms were created with the perspective set on Horizon Europe, with the aim of making Spanish groups more competitive in the new program. 

With the 2020 call, apart from the Biobanks and Biomodels platform, the ISCIII adds capabilities to the Clinical Research and Clinical Trials Platform (SCREN), which is now known as the ISCIII Support Platform for Clinical Research. On the other hand, in the commitment to the generation of industry and as an evolution of the technological innovation platform (ITEMAS), another platform is added with the aim to  facilitate the industrialization of the development and research of the National Health Service. Specifically, the announcement has financed the three Platforms with more than 27 million euros to be executed over the next 3 years. 



More information:
Àngels López: alopez@ibecbarcelona.eu